187034-31-7
187034-31-7 结构式
基本信息
CS-2628
TAPI2
TAPI 2
TNF Protease Inhibitor 2
TNF-ALPHA PROTEASE INHIBITOR-2
TAPI-2 (TNF Protease Inhibitor 2)
HONHCOCH2CH(CH2-CH(CH3)2)CO-T-LEU-ALA-NHCH2CH2NH2
N-(R)-(2-(HYDROXYAMINOCARBONYL)METHYL)-4-METHYLPENTANOYL-L-T-BUTYL-GLYCYL-L-ALANINE 2-AMINOETHYL AMIDE
N-(R)-[2-(HYDROXYAMINOCARBONYL)METHYL]-4-METHYLPENTANOYL-L-T-BUTYL-ALANYL-L-ALANINE, 2-AMINOETHYL AMIDE
N-[2-[2-(Hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-100211 | CS-2628 TAPI-2 | 187034-31-7 | 1mg | 1700元 |
| 2025/05/22 | HY-100211 | CS-2628 TAPI-2 | 187034-31-7 | 10 mM * 1 mLin DMSO | 5485元 |
| 2025/05/22 | HY-100211 | CS-2628 TAPI-2 | 187034-31-7 | 5mg | 6000元 |
常见问题列表
|
MMP 20 μM (IC 50 ) |
The hydroxamate-based metalloprotease inhibitor TAPI-2 bounds to hmeprin with inhibition constants IC 50 20±10 μM for hmeprin β subunit and 1.5±0.27 nM for hmeprin α subunit. Generally, hmeprin α is inhibited more strongly than the β subunit. Without affecting ADAM17 expression, TAPI-2 dramatically decreases the protein levels of NICD and its downstream target HES-1 in both HCP-1 and HT29 cells. Moreover, treating cells with TAPI-2 significantly decreases the CSC phenotype by -50% in both CRC cell lines. The dose-dependent effects of TAPI-2 on the sphere formation and protein levels of NICD and HES-1 confirm that the concentration used (20 μM) is within the effective dose range of TAPI-2 (5-40 μM).